Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 12 post-ruxolitinib window

Dashboard

Oura Digital Twin

Generated 2026-03-27 19:54 · Post-HSCT Patient

Continuous wearable monitoring via Oura Gen 3. 12 analysis modules run daily, producing interactive HTML reports with clinical-grade signal processing, causal inference, and predictive modeling.

HRV (RMSSD)

Critical

10.1ms

ESC threshold: 15 ms

Sleep Score

Abnormal

64.3

5.95 hrs avg duration

Readiness

Abnormal

65.2

SpO2

Normal

96.1%

Core

Heart rate, HRV, sleep, activity, SpO2, and readiness trends across the full observation window.

Biomarker Trends

Composite biomarker indices combining multiple Oura signals into clinical-grade scores.

Sleep architecture, staging distribution, efficiency, and circadian rhythm analysis.

Clinical

Causal: Ruxolitinib

Bayesian causal impact and interrupted time-series analysis of ruxolitinib response.

GvHD Prediction

Hidden Markov and state-space models predicting GvHD flare probability from wearable signals.

SpO2 trend monitoring and bronchiolitis obliterans syndrome screening thresholds.

Advanced

Frequency-domain HRV, Poincare plots, DFA, sample entropy, and autonomic balance metrics.

Unscented Kalman Filter digital twin tracking latent inflammatory and autonomic states.

Foundation Model

Chronos foundation model forecasting with prediction intervals and anomaly scoring.

Anomaly Detection

Matrix Profile, Isolation Forest, and CUSUM anomaly detection across biometric channels.

Interactive 3D scatter of sleep, HRV, and activity with treatment phase coloring.

Context

Methodology, limitations, and honest assessment of what this system can and cannot do.

Planned analyses, validation targets, and next steps for the digital twin platform.

All metrics derived from Oura Ring Gen 4 consumer wearable data. Not clinical-grade measurements.

Single-patient case study (N=1). Not validated for clinical decision-making. Not a medical device.

Data: January 08 – March 27, 2026 · Post-intervention: 12 days (ruxolitinib, March 16)

Open source under MIT License · © 2026 The Educational Equality Institute · GitHub